2型糖尿病及降糖药物与恶性肿瘤相关性的研究进展  

Research Progress on the Relationship between Type 2 Diabetes,Hypoglycemic Drugs and Malignant Tumors

作　　者：吴竟菲 韩立坤[2] Jingfei Wu;Likun Han(Clinical School of INNER MONGOLIA MINZU UNIVERSITY,Tongliao,Inner Mongolia 028000;Endocrinology Department of INNER MONGOLIA MINZU UNIVERSITY Affiliated Hospital,Tongliao,Inner Mongolia 028005)

机构地区：[1]内蒙古民族大学临床医学院,内蒙古通辽028000 [2]内蒙古民族大学附属医院内分泌科,内蒙古通辽028005

出　　处：《医学研究前沿》2024年第9期7-9,共3页Frontiers of Medical Research

摘　　要：随着社会发展和生活方式的变化,2型糖尿病的发病率正在不断升高,而其合并症更加严重,其中尤以恶性肿瘤是显著的并发疾病。本论文以2型糖尿病及降糖药物与恶性肿瘤的相关性为研究焦点,通过大量文献调查和统计分析,系统探讨了2型糖尿病及其治疗药物与肿瘤发生的关系。研究表明,2型糖尿病本身以及部分降糖药物可能通过影响胰岛素水平、胰岛素生长因子及其受体、炎症反应以及体重等多种途径增加恶性肿瘤的风险,但也有部分降糖药物如二甲双胍等可能具有抑制肿瘤的效应。对于2型糖尿病患者,针对于恶性肿瘤的个性化防治相当重要。研究结果提供了更深层次对2型糖糖尿病患者恶性肿瘤风险评估和治疗策略的认识,同时为未来降糖药物的选择和使用、以及糖尿病患者的肿瘤防治提供了参考。With the development of society and the change of lifestyle,the incidence rate of type 2 diabetes is increasing,and its complica-tions are more serious,especially malignant tumors.This paper focuses on the relationship between type 2 diabetes,hypoglycemic drugs and malignant tumors.Through a large number of literature surveys and statistical analysis,this paper systematically discusses the relationship between type 2 diabetes,its therapeutic drugs and tumor occurrence.Research shows that type 2 diabetes itself and some hypoglycemic drugs may increase the risk of malignant tumor by influencing insulin levels,insulin growth factors and their receptors,inflammatory reac-tions,weight and other ways,but some hypoglycemic drugs such as metformin may have tumor inhibitory effects.For patients with type 2 diabetes,personalized prevention and treatment of malignant tumors is very important.The research results provide a deeper understanding of the risk assessment and treatment strategies of malignant tumors in patients with type 2 diabetes mellitus diabetes,and provide a refer-ence for the selection and use of hypoglycemic drugs in the future,as well as cancer prevention and treatment in patients with diabetes.

关 键 词：2型糖尿病 降糖药物 恶性肿瘤 并发疾病 风险评估 

分 类 号：R587.1[医药卫生—内分泌]